Jounce Therapeutics is dedicated to transforming the treatment of cancer
Jounce is a physics term and refers to a major jolt in a new direction, in this case, leading to a paradigm shift in drug discovery, development and treatment for cancer.
We are discovering and developing novel cancer immunotherapies linked to patient selection strategies that are designed to mobilize the immune system to seek out and attack cancerous cells and tumors. Our translational science-based product engine has the potential to discover novel biological insights to drive the development of game-changing immunotherapy treatments with highly durable responses, extending and improving patients' quality of life.
Jounce Therapeutics Announces Presentation at the Leerink Partners Immuno-Oncology RoundtableRead More > >
Jounce Therapeutics Appoints Kim Drapkin, CPA as Chief Financial OfficerRead More > >
Lasker Foundation Gives Jounce Founder, James Allison, 2015 Lasker AwardRead More > >
Jounce Therapeutics to Present at the Bank of America Merrill Lynch 2015 Health Care ConferenceRead More > >
Jounce Therapeutics Secures $56 Million in Oversubscribed Series B FinancingRead More > >
Jounce Therapeutics to Present at the Jefferies 2015 Immuno-Oncology SummitRead More > >
Jounce Therapeutics to Present at the Cowen and Company 35th Annual Health Care ConferenceRead More > >
Jounce Therapeutics Appoints Deborah Law, D. Phil., to Chief Scientific OfficerRead More > >